Blog

RSS Feed
Posted by Michael Wonder on 23 Sep 2021

Canada should negotiate a fairer share of drug R&D costs

23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...

Read more →
Posted by Michael Wonder on 03 Dec 2018

Canadian R&D-to-sales ratio for brand-name drug companies less than half of 10% commitment

3 December 2018 - USMCA concessions latest hit to Canadian prescription drug costs. ...

Read more →
Posted by Michael Wonder on 04 Dec 2017

Brand name drug sales soar in Canada, while R&D sags

1 December 2017 - Patented drug industry disputes it's failing to invest enough into research and development. ...

Read more →